MDFI is a novel biomarker for poor prognosis in LUAD

BACKGROUND: Approximately 80% of lung cancers are non-small cell lung cancers (NSCLC). Lung adenocarcinoma (LUAD) is the main subtype of NSCLC. The incidence and mortality of lung cancer are also increasing yearly. Myogenic differentiation family inhibitor (MDFI) as a transcription factor, its role...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Pengyu, Quan, Zhen, Song, Xueyu, Gao, Zhaojia, Yuan, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589366/
https://www.ncbi.nlm.nih.gov/pubmed/36300089
http://dx.doi.org/10.3389/fonc.2022.1005962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589366/
https://www.ncbi.nlm.nih.gov/pubmed/36300089
http://dx.doi.org/10.3389/fonc.2022.1005962

Ejemplares similares